<DOC>
	<DOCNO>NCT01526694</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design determine efficacy safety combination chemotherapy consist Bendamustine + Dexamethasone + Thalidomide patient multiple myeloma ( MM ) patient treatment lenalidomide bortezomib ineligible one drug .</brief_summary>
	<brief_title>Multicenter Clinical Trial Investigate Efficacy Safety Bendamustine , Dexamethasone Thalidomide Relapsed Refractory Multiple Myeloma Patients After Treatment With Lenalidomide Bortezomib Which Are Ineligible One These Drugs</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Age 18 year time signing informed consent form . Life expectancy least 3 month Able adhere study visit schedule protocol requirement Relapsed refractory active MM ( accord International Myeloma Working Group guideline ) treatment contain bortezomib lenalidomide ineligible ( intolerance toxicity ) one drug detectable myeloma protein blood urine . Disease free prior malignancy least 5 year . All previous multiple myeloma treatment , include radiation , cytostatic therapy surgery , must discontinue least 4 week prior treatment study , except corticosteroid therapy . ECOG performance status &lt; 2 study entry , unless due MM . At least follow laboratory finding day treatment start : Platelet count ≥ 75 x 10^9/L without transfusional support within 7 day . Neutrophil count &gt; 1.5 x 10^9/L without GCSF . Corrected calcium ≤ 14 mg/dL ( 3.5 mmol/L ) . AST : ≤ 2.5 time normal upper limit . ALT : ≤ 2.5 time normal upper limit . Total bilirubin : ≤ 1.5 time normal upper limit . Measured calculate creatinine clearance ≥ 20 mL/minute Women child bear potential male patient whose partner woman child bear potential must prepare use two effective method contraception protocol treatment , commit absolute continuous abstinence.The pregnancy test must negative 1428 day 72 hour treatment start . Only case hysterectomy presence menopause least 24 consecutive month pregnancy test well contraception necessary . Men must father child 6 month follow cessation treatment must use condom . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Patients contraindication treatment bendamustine , dexamethasone thalidomide . Uncontrolled severe cardiovascular disease , include myocardial infarction within 6 month study entry , New York Heart Association Class III IV heart failure , uncontrolled angina severe uncontrolled ventricular arrhythmia ( ≥ Lown 3 ) . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide purine analogue Concurrent use anticancer agent treatment state treatment plan . Peripheral neuropathy grade ≥2 accord WHO Known positive HIV infectious hepatitis , type A , B C. Major surgery le 30 day start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>relapsed refractory multiple myeloma</keyword>
</DOC>